Navigation Links
012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007
Date:2/26/2008

/p>

Current maturities of long-term

obligations 3,558 11,497 925

Payables in respect of 012

acquisition - 584,621 -

Account payables 156,332 149,020 40,648

Loan from the Parent Company 105,733 - 27,492

Other payables and accrued

expenses 102,096 66,322 26,546

Total current liabilities 372,469 1,143,099 96,846

Long-term liabilities

Debentures 437,460 - 113,744

Long-term obligations 2,836 2,871 737

Long-term trade and other payables 20,458 1,365 5,320

Deferred taxes 41,526 49,855 10,797

Liability for employee severance

benefits 32,318 29,823 8,403

Total long-term liabilities 534,598 83,914 139,001

Total liabilities 907,067 1,227,013 235,847

Shareholders' equity and parent

company investment 655,108 144,549 170,335

Total liabilities shareholders'

equity and parent company

investment 1,562,175 1,371,562 406,182

012 Smile.Communications Ltd.

Consolidated Statements of Operations

Convenience

translation

into

U.S. dollars

$1 = NIS


'/>"/>

SOURCE 012 Smile.communications Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. 012 Smile.Communications to Deploy Extensive WiFi Internet Access System for Sheba Medical Center
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. Haemacure Reports Third Quarter 2007 Results
4. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
5. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
6. MDS Reports Third Quarter 2007 Results
7. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
8. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
9. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
11. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...EM, N.C., Nov. 20 Samue...o redefine what it means to be "happy" during the ...h a specialty in family counseling and chair of th...ty, Gladding says research shows that it is the pr... even depression during the holidays. ,, That,s...
(Date:11/20/2009)...ed online November 20 in the Journal of the Natio...ars and hopes that often appear in news coverage o... for both the media and journals to help alleviate...d Steven Woloshin, M.D., M.S., of Center for Medic...ealth Policy and Clinical Practice in New Hampshir...
(Date:11/20/2009)...) November 20, 2009Emergency medical service (EMS)...d 350,000 cardiac arrests each year. Only 5 to 10...survive. Better quality cardiopulmonary resuscita...ay be associated with better patient outcome. The...rgest clinical research network to study prehospit...
(Date:11/20/2009)...ne-third buying 90-day supply, study finds , ...a three-month supply of prescription drugs is up t..., according to a new study. , U.S. researchers ... between 2000 and 2005, and found that patients wh...th supply saved an average 29 percent in out-of-po...
(Date:11/20/2009)... Longtime OB/GYN warns against the new breast c...ative Services Task Force. These guidelines may be...an lives. When is it wrong to be safe than sorry? ...ve Services Task Force recommendations, published ...icine, has set off a firestorm in the medical comm...
Breaking Medicine News(10 mins):Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Three-Month Supply Lowers Drug Costs 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3
...al breakthroughs in recent decades have allowed he...nts to live longer. But as their hearts decline in...will experience disability and the need for nursin...ty among people with CHF, as well as the implicati...
...d sense of smell is an early indicator of Parkinso...st can help determine if people with no symptoms e...d be like diagnosing coronary artery disease befor...kinsons Associated Risk Syndrome Study. With Parki...
...nal Health, Inc.,(NYSE: CAH ), a global provider ...nd productivity of health care, plans to release s...ay, Jan. 29, prior to the opening of,trading on th...orresponding slide,presentation, go to the Investo...
...way Clinical Laboratories, (http://www.parkwayclin...ed,clinical reference laboratory located in Bensal...g Mats Sanden, M.D., as medical director, Masood,H...e New Year with a resolve to rapidly grow our vari...
...MedPredict Market Research, a,global provider of p...research, has published "Thought Leader Insight & ...trategic insight for pharma and biotech,companies ...nd cardiovascular disease, however, the,medical ju...
...le in Spanish . , A group of scientists led by ...istry and Molecular Biology at Universitat Autnoma..., an enzyme that is detected in large quantities o...ous. Thus this molecule would serve as a good mark...
Other Medicine News:Health News:Congestive heart failure leads to greater disability, nursing home admissions 2Health News:Risk factors for Parkinson's disease under study 2Health News:Cardinal Health to Announce Second-Quarter Results on January 29 2Health News:Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening 2Health News:Pipeline for New Obesity Therapies is Focus of New Report 2Health News:UAB research could improve the prognosis and treatment of lung cancer 2
(Date:11/20/2009)...ICK, Mass. and LONDON, Nov. 20 /PRNewswire-FirstCa...) today announced that it has received 510(k) clea...FDA) and CE Mark approval to market its WallFlex&#...ent of malignant esophageal strictures (obstructio...r non-resectable esophageal cancer. ,, (Photo:...
(Date:11/20/2009)...YMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswir...icle that questions why currently available medica...re being ignored, ECRI Institute, an independent n...e evidence on Finasteride for Prevention of Prost...r 13, 2009, New York Times article, " Drugs to D...
(Date:11/20/2009)...NCETON, N.J., Nov. 20 So...x or the Company), formerly known as DOR BioPharma...ced today that it has formed a consortium to devel...d other rapidly acting vaccines. Soligenix receive... of Allergy and Infectious Diseases (NIAID), a div...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 1Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 2Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 3Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 4T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 1T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 2T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 3Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 1Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 2Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 3
...uly 16 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP )...2 study evaluating the safety, tolerability and,ph... published in the July,issue of Current Medical Re...ing MAP0004, an orally inhaled and self-administer..., The study results, which were first announced l...
...ble Phase 1 RX-3341 Results -, NEW HAVEN, Conn., ...he "Company"), a development-stage company focused...tics for the treatment of,antibiotic-resistant inf...,2 clinical trial for an intravenous form of antib...ated skin and skin structure infections (cSSSIs).,...
Other Medicine Technology:MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3
ENDOLOOP Suture Type - 0 PDSII
ENDOLOOP Suture Type - 0 Coated VICRYL
HemoCue 201 DM System, Glucose
Bartels® C. Difficile Toxin A Antigen EIA with Controls
Medicine Products: